A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 911-916

  Kamani, N ^a,d   August, C S ^a   Bunin, N ^b   Leahey, A ^b   Bayever, E ^b   Goldwein, J ^b   Zusman, J ^c   Evans, A E ^b   D'Angio, G ^b  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Mt Sinai Medical Center   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

BMT; Neuroblastoma; TBI; Thiotepa

Indexed keywords

CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GENTAMICIN; IMMUNOGLOBULIN; METHOTREXATE; NYSTATIN; TENIPOSIDE; THIOTEPA; VANCOMYCIN; VINCRISTINE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER VENOOCCLUSIVE DISEASE; MUCOSA INFLAMMATION; NEUROBLASTOMA; ORAL DRUG ADMINISTRATION; PAIN; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SIBLING; SKIN TOXICITY; SURVIVAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; PROGNOSIS; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 0030058442     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Evans AE, D'Angio GJ. Propert K et al. Prognostic factors in neuroblastoma. Cancer 1987; 59: 1853-1859.
2. Silber JH, Evans AE, Fridman M: Models to predict outcome from childhood neuroblastoma: The role of serum ferritin and tumor histology. Cancer Res 1991; 51: 1426-1433.
3. Hann H-WL, Evans AE, Siegel SE et al. Prognostic importance of serum ferritin in patients with stage III and IV neuroblastoma: the Children's Cancer Study Group experience. Cancer Res 1985; 45: 2843-2848.
4. Shimada H, Chatten J, Newton WA et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405-413.
5. Seeger RDC, Brodeur GM, Sather H et al. Association of multiple copies of N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 1985; 313: 1111-1116.
6. Look AT, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and n-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
7. Chan HSL, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl J Med 1991; 325: 1608-1614.
8. Nakagawara A, Arima-Nakagawara M, Scavarda NJ et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. New Engl J Med 1993; 328: 847-854.
9. August CS, Auble B. Autologous bone marrow transplantation for advanced neuroblastoma at the Children's Hospital of Philadelphia: An update. In: Dicke K et al (eds). Autologous Bone Marrow Transplantation. Proc 4th Int Symp, Univ Texas, MD Anderson Cancer Center, 1989, pp 567-573.
10. August CS, Serota FT, Koch PA et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2: 609-616.
11. Evans AE, August CS, Kamani N et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: An update. Med Pediatr Oncol 1994; 23: 323-327.
12. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the International criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
13. Kamani N, August CS. Management of problems of bone marrow transplantation. In: D'Angio GJ, Sinniah D, Meadows AT, Evans AE, Pritchard J (eds). Practical Pediatric Oncology, 1992, pp 114-127.
14. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared to cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
15. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70-73.
16. Graham-Pole J, Gee A, Janssen W et al. Immunomagnetic purging of bone marrow: a model for negative cell selection. Am J Pediatr Hematol Oncol 1990; 12: 257-261.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 958; 53: 457-481.
18. Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-1058.
19. Saarinen UM, Hovi L, Makipernaa A et al. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant 1991; 8: 369-376.
20. Graham-Pole J, August CS, Ramsay N et al Is there an advantage to allogeneic over autologous marrow transplantation in patients with metastatic neuroblastoma? Exp Hematol 1989; 17: 586 (abstr.).
21. Ladenstein R, Lasset C, Hartmann O et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 37-46.
22. Matthay KK, Seeger RC, Reynolds CP et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 1994; 12: 2382-2389.
23. Johnson FL, Goldman S. Role of autotransplantation in neuroblastoma. Hematol Oncol Clin N Amer 1993; 7: 647-662.
24. Graham-Pole J. Myeloablative treatment supported by marrow infusions for children with neuroblastoma. In: Armitage JO, Antman KH (eds). High Dose Cancer Therapy. Pharmacology, Hematopoietins, Stem Cells. Williams & Wilkins: Baltimore, 1992, pp 735-749.
25. Graham-Pole J, Casper J, Elfenbein G et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 1991; 9: 152-158.
26. Philip T, Zucker JM, Bernard JL et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991; 9: 1037-1044.
27. Ladenstein R, Favrot M, Lasset C et al. Indication and limits of megatherapy and bone marrow transplantation in high risk neuroblastoma. A single centre analysis of prognostic factors. Eur J Cancer 1993; 29: 947-956.
28. Pinkerton CR, Zucker JM, Hartmann O et al. On behalf of the European Neuroblastoma Study Group (ENSG). Short duration, high-dose, alternating chemotherapy in metastatic neuroblastoma (ENSG 3C regimen). Br J Cancer 1990; 62: 319-323.
29. Berthold F, Burdach S, Kremens B et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Pediatr 1990; 202: 262-269.
30. Seeger RC, Villablanca JG, Matthay KK et al. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1992; 366: 527-533.
31. Matthay KK, Atkinson JB, Stram DO et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol 1993; 11: 2226-2233.
32. Willi SM, Cooke K, Goldwein J et al. Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth after transplantation for leukemia or aplastic anemia. J Pediatr 1992; 120: 726-732.